


International Nonproprietary Names for Pharmaceutical Substances

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances (see Annexes), the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals Unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 66 Prop. INN not later than 31 August 1992**.

Proposed International Nonproprietary Names: List 66

Lists of proposed (1–58) and recommended (1–27) international nonproprietary names can be found in Cumulative List No. 7, 1988.

<i>Proposed International Nonproprietary Name (Latin, English)</i>	<i>Chemical Name or Description, Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use*</i>
albifyllinum albifylline	1-(5-hydroxy-5-methylhexyl)-3-methylxanthine C ₁₃ H ₂₀ N ₄ O ₃ 107767-55-5 <i>polymorphonuclear neutrophil modulator</i>
	


* *Action and Use: The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will be neither revised nor included in the Cumulative Lists of INNs.*

Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


alosetronum
alosetron

2,3,4,5-tetrahydro-5-methyl-2-[(5-methylimidazol-4-yl)methyl]-1H-
pyrido[4,3-b]indol-1-one
C₁₇H₁₈N₄O 122852-42-0 *antiemetic, anxiolytic*




atovaquonum
atovaquone

2-[*trans*-4-(*p*-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
C₂₂H₁₉ClO₃ 95233-18-4 *antimalarial*




batebulastum
batebulast

p-*tert*-butylphenyl *trans*-4-(guanidinomethyl)cyclohexanecarboxylate
C₁₉H₂₉N₃O₂ 81907-78-0 *asthmatic*




befloxatonum
befloxatone

(*R*)-5-(methoxymethyl)-3-[*p*-[(*R*)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-
oxazolidinone
C₁₅H₁₈F₃NO₅ 134564-82-2 *antidepressant*



betadexum
betadex

β -cyclodextrin
C₄₂H₇₀O₃₅ 7585-39-9 pharmaceutical aid




biciromabum
biciromab

mouse T2G1s cell anti-human fibrin II β -chain monoclonal immunoglobulin G
Fab' fragment
diagnostic agent


brimonidinum
brimonidine

5-bromo-6-(2-imidazolidinylidenamino)quinoxaline
C₁₁H₁₀BrN₅ 59803-98-4 α_2 -adrenoreceptor agonist




calcii levofolinas
calcium levofolinate

calcium *N*-[*p*-[[[(6*S*)-2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-
pteridiny]methyl]amino]benzoyl]-*L*-glutamate (1:1)
C₂₀H₂₁CaN₇O₇ 80433-71-2 antineoplastic




cebaracetamum
cebaracetam

(±)-4-[[4-(*p*-chlorophenyl)-2-oxo-1-pyrrolidinyl]acetyl]-2-piperazinone
C₁₆H₁₈ClN₃O₃ 113957-09-8 nootropic agent




cefditorenium
cefditoren

(+)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-3-[(*Z*)-2-(4-methyl-5-thiazolyl)vinyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7²-(*Z*)-(O-methyloxime)
C₁₉H₁₈N₆O₅S₃ 104145-95-1 antibiotic




cefzopranum
cefzopran

(-)-1-[[6*R*,7*R*)-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1*H*-imidazo[1,2-*b*]pyridazin-4-ium hydroxide inner salt, 7²-(*Z*)-(O-methyloxime)
C₁₉H₁₇N₉O₅S₂ 113359-04-9 antibiotic




cilnidipinum
cilnidipine

(±)-(*E*)-cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate
C₂₇H₂₈N₂O₇ 132203-70-4 calcium channel blocker




derigidolum
derigidole

(+)-1,2,4,5-tetrahydro-2-(2-imidazolin-2-yl)-2-propylpyrrolo[3,2,1-*h*]indole
C₁₆H₂₁N₃ 122830-14-2 antidiabetic, α₂-adrenoreceptor antagonist



dexfososerinum
dexfososerine

L-serine dihydrogen phosphate (ester)
C₃H₈NO₆P 407-41-0 nootropic agent




dorlimomab aritoxum
dorlimomab aritox

ricin A chain-antibody ST 1 F(ab')₂ fragment immunotoxin
immunomodulator


efonidipinum
efonidipine

2-(*N*-benzylamino)ethyl (±)-1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-5-phosphononcontinate, cyclic 2,2-dimethyltrimethylene ester
 $C_{34}H_{38}N_3O_7P$ 111011-63-3 *calcium channel blocker*




eliprodilum
eliprodil

(±)-*α*-(*p*-chlorophenyl)-4-(*p*-fluorobenzyl)-1-piperidineethanol
 $C_{20}H_{23}ClFN_2O$ 119431-25-3 *N-methyl-D-aspartate antagonist*




emakalimum
emakalim

(-)-(3*S*,4*R*)-3-hydroxy-2,2-dimethyl-4-(2-oxo-1(2*H*)-pyridyl)-6-chromancarbonitrile
 $C_{17}H_{16}N_2O_3$ 129729-66-4 *potassium channel activator*



emitefurum
emitefur

m-[[3-(ethoxymethyl)-5-fluoro-3,6-dihydro-2,6-dioxo-1(2*H*)-pyrimidinyl]-carbonyl]benzoic acid, 2-ester with 2,6-dihydroxynicotinonitrile, benzoate (ester)
 $C_{28}H_{19}FN_4O_8$ 110690-43-2 *antineoplastic*



Proposed International
Nonproprietary Name
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

ersoferminum
ersofermin

N-(*N*-glycyl-L-threonyl)basic fibroblast growth factor
(human clone λ KB7/ λ HFL1 precursor reduced)
 $C_{775}H_{1220}N_{220}O_{223}S_7$ 111212-85-2 *growth factor*


formestanum
formestane

4-hydroxyandrost-4-ene-3,17-dione
 $C_{19}H_{26}O_3$ 566-48-3 *aromatase inhibitor*




gadobutrolum
gadobutrol

[10-[2,3-dihydroxy-1-(hydroxymethyl)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)]gadolinium
 $C_{18}H_{31}GdN_4O_9$ 138071-82-6 *paramagnetic contrast medium*




idraprilum
idrapril

(1*S*,2*R*)-2-[[[(hydroxycarbonyl)methyl]methyl]methylcarbamoyl]cyclohexane =
carboxylic acid
 $C_{11}H_{18}N_2O_5$ 127420-24-0 *angiotensin-converting-enzyme inhibitor*



ilatreatidum
ilatreatide

N-(1-deoxy-4-*O*- α -D-glucopyranosyl-D-fructopyranosyl-1-yl)-D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-*N*-[(1*R*,2*R*)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteinamide cyclic (2 \rightarrow 7)-disulfide
 $C_{61}H_{86}N_{10}O_{20}S_2$ *antiulcer agent*



Proposed International
Nonproprietary Name
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

imciromabum
imciromab

mouse R11D10 cell monoclonal α -chain containing immunoglobulin G2a,
anti-human cardiac myosin heavy chain
126132-83-0 *immunomodulator*


imiquimodum
imiquimod

4-amino-1-isobutyl-1*H*-imidazo[4,5-*c*]quinoline
C₁₄H₁₆N₄ 99011-02-6 *antiviral*




iomazenilum (¹²³I)
iomazenil (¹²³I)

ethyl 5,6-dihydro-7-iodo-¹²³I-5-methyl-6-oxo-4*H*-imidazo[1,5-*a*][1,4]benzo=
diazepine-3-carboxylate
C₁₅H₁₄¹²³I₃N₃O₃ 127396-36-5 *benzodiazepine-receptor antagonist,*
diagnostic agent




isomolpanum
isomolpan

(±)-*trans*-1,3,4,4a,5,10b-hexahydro-4-propyl-2*H*-[1]benzopyrano=
[3,4-*b*]pyridin-9-ol
C₁₅H₂₁NO₂ 107320-86-5 *antipsychotic*



itopridum
itopride

N-[*p*-[2-(dimethylamino)ethoxy]benzyl]veratramide
C₂₀H₂₆N₂O₄ 122898-67-3 *digestive*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


lamivudinum
lamivudine

(-)-1-[(2*R*,5*S*)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
C₈H₁₁N₃O₃S 134678-17-4 *antiviral*



lanoconazolium
lanoconazole

(±)-*a*-[(*E*)-4-(*o*-chlorophenyl)-1,3-dithiolan-2-ylidene]imidazole-1-acetonitrile
C₁₄H₁₀ClN₃S₂ 101530-10-3 *antifungal, dermatological*




lazabemidum
lazabemide

N-(2-aminoethyl)-5-chloropicolinamide
C₈H₁₀ClN₂O 103878-84-8 *antiparkinsonian*




lesopitronum
lesopitron

2-[4-[4-(4-chloropyrazol-1-yl)butyl]-1-piperazinyl]pyrimidine
C₁₅H₂₁ClN₆ 132449-46-8 *anxiolytic*




levcromakalimum
levcromakalim

(3*S*,4*R*)-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromancarbonitrile
C₁₆H₁₈N₂O₃ 94535-50-9 *potassium channel activator*




lifarizinum
lifarizine

1-(diphenylmethyl)-4-[(5-methyl-2-*p*-tolylimidazol-4-yl)methyl]piperazine
C₂₉H₃₂N₄ 119514-66-8 *vasodilator*



losartanum
losartan

2-butyl-4-chloro-1-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol
C₂₂H₂₃ClN₆O 114798-26-4 *angiotensin II receptor antagonist*



maslimomabum
maslimomab


mouse monoclonal immunoglobulin G2b₁ anti-human T-cell receptor
 α/β chain
127757-92-0 *immunomodulator*

mecaserminum
mecasermin

insulin-like growth factor I (human)
C₃₃₁H₅₁₂N₉₄O₁₀₁S₇ 68562-41-4 *growth factor*

miboplatinum
miboplatin

(-)-*cis*-[(*R*)-2-(aminomethyl)pyrrolidine](1,1-cyclobutanedicarboxylato)=
platinum
C₁₁H₁₆N₂O₄Pt 103775-75-3 *antineoplastic*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

mosapridum
mosapride

(±)-4-amino-5-chloro-2-ethoxy-*N*-[[4-(*p*-fluorobenzyl)-2-morpholinyl]
methyl]benzamide
 $C_{21}H_{25}ClFN_3O_3$ 112885-41-3 *digestive*



nartograstimum
nartograstim


N-L-methionyl-1-L-alanine-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine =
colony-stimulating factor (human clone 1034)
 $C_{850}H_{1344}N_{226}O_{245}S_8$ 134088-74-7 *immunomodulator*
(for non-glycosylated protein)

nebacumabum
nebacumab

immunoglobulin M (human monoclonal HA-1A anti-endotoxin), disulfide with
human monoclonal HA-1A α -chain, pentameric dimer
138661-01-5 *immunomodulator*


necopidemum
necopidem

N-[[2-(*p*-ethylphenyl)-6-methylimidazo[1,2-*a*]pyridin-3-yl]methyl]-*N*,3-
dimethylbutyramide
 $C_{23}H_{29}N_3O$ 103844-77-5 *anaesthetic*



nevirapinum
nevirapine

11-cyclopropyl-5,11-dihydro-4-methyl-6*H*-dipyrido[3,2-*b*:2',3'-*e*][1,4]diazepin-
6-one
 $C_{15}H_{14}N_4O$ 129618-40-2 *antiviral*



Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


odalprofenum
odalprofen

methyl (\pm)-*m*-(α -imidazol-1-ylbenzyl)hydratropate

$C_{20}H_{20}N_2O_2$

137460-88-9

*nonsteroidal anti-inflammatory,
analgesic*




pentetreotidum
pentetreotide

N-[2-[[2-[bis(carboxymethyl)amino]ethyl](carboxymethyl)amino]ethyl]-*N*-(carboxymethyl)glycyl-*D*-phenylalanyl-L-cysteinyl-L-phenylalanyl-*D*-tryptophyl-L-lysyl-L-threonyl-*N*-[(1*R*,2*R*)-2-hydroxy-1-(hydroxymethyl)propyl]-L-cysteineamide cyclic (3→8)-disulfide

$C_{63}H_{87}N_{13}O_{19}S_2$

138661-02-6

diagnostic agent, antineoplastic



perflubronum
perflubron

1-bromoheptadecafluorooctane

C_8BrF_{17}

423-55-2

contrast medium

$F_3C-(CF_2)_6-CF_2Br$


perfosfamidum
perfosfamide

(\pm)-*cis*-2-[bis(2-chloroethyl)amino]tetrahydro-2*H*-1,3,2-oxazaphosphorin-4-yl hydroperoxide, *P*-oxide

$C_7H_{15}Cl_2N_2O_4P$

62435-42-1

antineoplastic




pivagabinum
pivagabine

4-pivalamidobutyric acid

$C_9H_{17}NO_3$

69542-93-4

antiparkinsonian, anticonvulsant




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

plomestanium
plomestane

10-(2-propynyl)estr-4-ene-3,17-dione
 $C_{21}H_{26}O_2$ 77016-85-4


antineoplastic



polaprezincum
polaprezinc

catena-poly[zinc- μ -[β -alanyl-L-histidinato(2-)-N,N',O:N^T]]
 $(C_9H_{12}N_4O_3Zn)_n$ 107667-60-7


antiulcer agent



poliglecapronum
poliglecaprone

2-oxepanone polymer with *p*-dioxane-2,5-dione
"m" and "n" are the numerical values representing the mol percentages of the monomers. The value of "m" should be given as a figure after the INN, e.g. "poliglecaprone 90", which means "m = 90" and "n = 10".
 $(C_6H_{10}O_2)_m(C_4H_4O_4)_n$ 41706-81-4

pharmaceutical aid




poliglusamum
poliglusam

chitosan

9012-76-4


haemostatic



pranidipinum
pranidipine

(*E*)-cinnamyl methyl (\pm)-1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate
 $C_{25}H_{24}N_2O_6$ 99522-79-9

calcium channel blocker



Proposed International
Nonproprietary Name
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

racephedrinum
racedrine

(±)-ephedrine
C₁₀H₁₅NO

90-81-3

sympathomimetic




remikirenum
remikiren

(*αS*)-*α*-[(*αS*)-*α*-[(*tert*-butylsulfonyl)methyl]hydrocinnamamido]-*N*-[(1*S*,2*R*,3*S*)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]imidazole-4-propionamide

C₃₃H₅₀N₄O₆S

126222-34-2

renin inhibitor




rocuronii bromidum
rocuronium bromide

1-allyl-1-(3*α*,17*β*-dihydroxy-2*β*-morpholino-5*α*-androstan-16*β*-yl)pyrrolidinium bromide, 17-acetate

C₃₂H₅₃BrN₂O₄

119302-91-9

neuromuscular receptor antagonist




romergolinum
romergoline

4-[(9,10-didehydro-6-methylergolin-8*β*-yl)methyl]-2,6-piperazinedione

C₂₀H₂₂N₄O₂

107052-56-2

antiparkinsonian, antipsychotic



Proposed International
Nonproprietary Name
(Latin, English)


Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

sargramostimum
sargramostim

23-L-leucinecolony-stimulating factor 2 (human clone pHG25 protein moiety)
C₆₃₉H₁₀₀₂N₁₆₈O₁₉₆S₈ 123774-72-1 immunomodulator
(for non-glycosylated protein)

seproxetinum
seproxetine

(S)-3-phenyl-3-[(a,a,a-trifluoro-p-tolyl)oxy]propylamine
C₁₆H₁₆F₃NO 126924-38-7 antidepressant




sevirumabum
sevirumab

human monoclonal immunoglobulin G1, α -chain, anti-cytomegavirus
immunomodulator

simendanum
simendan

mesoxalonitrile (\pm)-[p-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazone
C₁₄H₁₂N₆O 131741-08-7 cardiac stimulant




somfaseporum
somfasepor

8-190 growth hormone (pig)
C₉₃₈H₁₄₆₅N₂₅₇O₂₇₈S₆ 129566-95-6 growth hormone (vet.)

tacrolimusum
tacrolimus

(-)-(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-8-allyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-[(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxa = azacyclotricosine-1,7,20,21(4H,23H)-tetrone
C₄₄H₆₉NO₁₂ 104987-11-3 immunosuppressant




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*

tamolarizinum
tamolarizine

(±)- α -(3,4-dimethoxyphenyl)-4-(diphenylmethyl)-1-piperazineethanol
C₂₇H₃₂N₂O₃ 128229-52-7 *nootropic agent*




telimomabum aritoxum
telimomab aritox

ricin A chain-antibody T 101 Fab fragment immunotoxin
117305-33-6 *immunosuppressant*


terlakirenum
terlakiren

isopropyl (α , R , β , S)- α -hydroxy- β -[(R)-3-(methylthio)-2-[(S)- α -4-morpholinecarboxamidohydrocinnamido]propionamido]propionamido]-
cyclohexanebutyrate
C₃₁H₄₈N₄O₇S 119625-78-4 *renin inhibitor*




tetrofosminum
tetrofosmin

ethylenebis[bis(2-ethoxyethyl)phosphine]
C₁₈H₄₀O₄P₂ 127502-06-1 *diagnostic agent*



tolcaponum
tolcapone

3,4-dihydroxy-4'-methyl-5-nitrobenzophenone
C₁₄H₁₁NO₅ 134308-13-7 *antiparkinsonian*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


tretinoinum tocoferilum
tretinoin tocoferil

(±)-(2*R**)-2,5,7,8-tetramethyl-2-[(4*R**,8*R**)-4,8,12-trimethyltridecyl]-6-
chromanyl retinoate
C₄₉H₇₆O₃ 40516-48-1 vitamin




trimegestonum
trimegestone

17β-(*S*)-lactoyl-17-methylestra-4,9-dien-3-one
C₂₂H₃₀O₃ 74513-62-5 progestogen



tucaresolum
tucaresol

α-(2-formyl-3-hydroxyphenoxy)-*p*-toluic acid
C₁₅H₁₂O₅ 84290-27-7 antianaemic




tuvirumabum
tuvirumab

human monoclonal immunoglobulin G1, λ-chain, anti-hepatitis B virus
surface antigen

immunomodulator

unoprostonum
unoprostone

(+)-(Z)-7-[(1*R*,2*R*,3*R*,5*S*)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-
heptenoic acid
C₂₂H₃₈O₅ 120373-36-6 *antiglaucoma*




Proposed International
Nonproprietary Name
(Latin, English)

Chemical Name or Description, Molecular and Graphic formulae
Chemical Abstracts Service (CAS) registry number
Action and Use*


velaresolum
velaresol

5-(2-formyl-3-hydroxyphenoxy)valeric acid
 $C_{12}H_{14}O_5$ 77858-21-0 *antianaemic*




zalcitabinum
zalcitabine

2',3'-dideoxycytidine
 $C_9H_{13}N_3O_3$ 7481-89-2 *antiviral*




zaldaridum
zaldaride

(±)-1-[1-[(4-methyl-4*H*,6*H*-pyrrolo[1,2-*a*][4,1]benzoxazepin-4-yl)methyl]-4-piperidyl]-2-benzimidazolinone
 $C_{26}H_{28}N_4O_2$ 109826-26-8 *antidiarrhoeal*



zoniclezolum
zoniclezole

5-chloro-3-(1-imidazol-1-ylethyl)-1,2-benzisoxazole
 $C_{12}H_{10}ClN_3O$ 121929-20-2 *anticonvulsant*




Names for Radicals and Groups

Some substances for which a proposed International Nonproprietary Name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed International Nonproprietary Names.

buciclas
buciclate

trans-4-butylcyclohexanecarboxylate
 $C_{11}H_{19}O_2$



**AMENDMENTS
TO PREVIOUS LISTS**

Supplement to WHO Chronicle, Vol. 34, No. 9, 1980

Proposed International Nonproprietary Names (Prop. INN): List 44

p. 12 felodipinum
felodipine

replace the chemical name and the CAS registry number by the following:

(±)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-
3,5-pyridinedicarboxylate
86189-69-7


Supplement to WHO Chronicle, Vol. 39, No. 5, 1985

Proposed International Nonproprietary Names (Prop. INN): List 53

p. 12 glimepiridum
glimepiride

replace the chemical name and the graphic formula by the following:

1-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)=
ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea



WHO Drug Information, Vol. 1, No. 2, 1987

Proposed International Nonproprietary Names (Prop. INN): List 57

p. 104 ramoplaninum
ramoplanin

replace the description, molecular formula and CAS registry number by the following:

glycopeptide antibiotic produced by *actinoplanes* species ATCC33076
Ramoplanin is a complex antibiotic consisting of a main component
designated as ramoplanin A₂ and a small amount of related substances,
ramoplanin A₁ and A₃.

C₁₁₂₋₁₂₀H₁₄₂₋₁₅₆N₂₁O₃₅₋₄₀ 76168-82-6

WHO Drug Information, Vol. 2, No. 4, 1988

Proposed International Nonproprietary Names (Prop. INN): List 60

p. 15 delete
orlipastatum
orlipastat


insert
orlistatum
orlistat

Proposed International Nonproprietary Names (Prop. INN): List 62

- p. 6 epoetin alfa *replace the description by the following:*
 epoetin alfa human 1-165-erythropoietin, glycoform α

Proposed International Nonproprietary Names (Prop. INN): List 63

- p. 4 cilobradinum *delete the CAS registry number and replace the chemical name and the*
 cilobradine *graphic formula by the following:*
 (+)-(S)-3-[[1-(3,4-dimethoxyphenethyl)-3-piperidyl]methyl]-1,3,4,5-tetrahydro-7,8-
 dimethoxy-2H-3-benzazepin-2-one



Proposed International Nonproprietary Names (Prop. INN): List 64

- p. 7 corticorelinum *replace the description, molecular and graphic formula by the following:*
 corticorlin corticotropin-releasing factor; the species specificity should be indicated in
 brackets behind the name e.g.:

corticorelin (human)
 $C_{208}H_{344}N_{60}O_{63}S_2$

H — Ser — Glu — Glu — Pro — Pro — Ile — Ser — Leu — Asp — Leu — Thr — Phe — His — Leu —
 Leu — Arg — Glu — Val — Leu — Glu — Met — Ala — Arg — Ala — Glu — Gln — Leu — Ala —
 Gln — Gln — Ala — His — Ser — Asn — Arg — Lys — Leu — Met — Glu — Ile — Ile — NH₂


corticorelin (ovine)
 $C_{205}H_{339}N_{59}O_{63}S$

H — Ser — Gln — Glu — Pro — Pro — Ile — Ser — Leu — Asp — Leu — Thr — Phe —
 His — Leu — Leu — Arg — Glu — Val — Leu — Glu — Met — Thr — Lys — Ala —
 Asp — Gln — Leu — Ala — Gln — Gln — Ala — His — Ser — Asn — Arg — Lys —
 Leu — Leu — Asp — Ile — Ala — NH₂

- p. 12 lenograstimum *insert the following CAS registry number:*
 lenograstim 135968-09-1

p. 20 racementolum
racementol

replace the graphic formula by the following:



p. 27 fendizoatum
fendizoate

delete the CAS registry number:

p. 27 loprazolamum
loprazolam

replace the CAS registry number by the following:


61197-73-7

WHO Drug Information, Vol. 5, No. 2, 1991

Proposed International Nonproprietary Names (Prop. INN): List 65

p. 9 naglivanum
naglivan

replace the graphic formula by the following:




p. 10 polifeprosanum
polifeprosan

add the following:

"m" and "n" are the numerical values representing the mass percentages of the monomers. The value of "m" should be given as a figure after the INN, e.g. "polifeprosan 20", which means "m = 20" and "n = 80".

p. 17 cetorelixum
cetorelix

replace the graphic formula by the following:



p. 19 terikalantum
terikalant

replace the chemical name by the following:

(-)-(S)-1-[2-(4-chromanyl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine

Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* appeared in list 65 of proposed INN and will appear again in the next list.